Back
Byrna Technologies 10K Form
Buy
54
BYRN
Byrna Technologies
Last Price:
19.39
Seasonality Move:
20%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2021-04-12 | 10Q | BYRN/Byrna Technologies Quarterly |
| 2021-02-26 | 10K | BYRN/Byrna Technologies Annual |
| 2020-10-09 | 10Q | BYRN/Byrna Technologies Quarterly |
| 2020-07-20 | 10Q | BYRN/Byrna Technologies Quarterly |
| 2020-06-03 | 10Q | BYRN/Byrna Technologies Quarterly |
| 2020-05-18 | 10K | BYRN/Byrna Technologies Annual |
Receive BYRN News And Ratings
See the #1 stock for the next 7 days that we like better than BYRN
BYRN Financial Statistics
Sales & Book Value
| Annual Sales: | $42.64M |
|---|---|
| Cash Flow: | $-2.09M |
| Price / Cash Flow: | 43.58 |
| Annual Sales: | $1.98 |
| Price / Book: | 9.62 |
Profitability
| EPS (TTM): | 0.09070 |
|---|---|
| Net Income (TTM): | $2.29M |
| Gross Margin: | $23.65M |
| Return on Equity: | 5.26% |
| Return on Assets: | 4.22% |
Byrna Technologies Earnings Forecast
Key Byrna Technologies Financial Ratios
- The Gross Profit Margin over the past 17 years for BYRN is 55.45%.
- The Selling, General & Administrative Expenses for BYRN have been equal to 0.00% of Gross Profit Margin.
- The Interest Expense is -0.91% of Operating Income.
- The Net Earning history of BYRN is -19.21% of Total Revenues.
- Per Share Earnings over the last 19 years have been positive in 9 years.
Byrna Technologies Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Aerospace & Defense |
| Sector: | Industrials |
| Current Symbol: | BYRN |
| Website: | byrna.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 3.51 |
| Quick Ratio: | 1.77 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 95.3 |
BYRN Technical Analysis vs Fundamental Analysis
Buy
54
Byrna Technologies (BYRN)
is a Buy
Is Byrna Technologies a Buy or a Sell?
-
Byrna Technologies stock is rated a Buy
The current Byrna Technologies [BYRN] share price is $19.34. The Score for BYRN is 54, which is 8% above its historic median score of 50, and infers lower risk than normal.